Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia

Kwang Kon Koh, Michael J. Quon, Soo Lim, Yonghee Lee, Ichiro Sakuma, Youn Hee Lee, Seung Hwan Han, Eak Kyun Shin

Research output: Contribution to journalArticle

25 Scopus citations


Background: We investigated effects of fenofibrate therapy on endothelial dysfunction and adipocytokine profiles. Methods: A randomized, single-blind, placebo-controlled, cross-over study was conducted in 53 patients with primary hypertriglyceridemia. We administered placebo or fenofibrate 160 mg daily for 8 weeks. Results: When compared with placebo, fenofibrate therapy substantially lowered plasma levels of TNF-α by 6 ± 3% (P= 0.014) and hsCRP from 1.10 to 0.90 mg/l (P= 0.004). When compared with placebo, fenofibrate therapy increased plasma levels of adiponectin by 17 ± 4% (P= 0.001), insulin sensitivity by 4 ± 1% (as assessed by QUICKI, P= 0.009), and decreased plasma levels of leptin and resistin by 4 ± 7% (P= 0.022) and 10 ± 3% (P= 0.001), respectively. There were correlations between percent changes in QUICKI and percent changes in adiponectin levels (r= 0.279, P= 0.043) or leptin (r= -0.280, P= 0.042). Conclusions: Fenofibrate therapy significantly reduced pro-inflammatory biomarkers and improved adipocytokines levels and insulin sensitivity in hypertriglyceridemic patients.

Original languageEnglish
Pages (from-to)144-147
Number of pages4
Issue number1
StatePublished - 1 Jan 2011


  • Adipocytokines
  • Endothelial function
  • Fenofibrate
  • Hypertriglyceridemia
  • Insulin resistance

Cite this